305results about How to "Reduce appetite" patented technology

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

A method is provided for treating a subject. The method includes administering to the subject an ingestible capsule containing one or more flexible support elements adapted to expand while in a stomach of the subject, thereby bringing a plurality of electrodes into contact with a wall of the stomach. The method also includes driving the electrodes to apply an electrical signal to the stomach wall at first and second times, the second time at last 24 hours after the first time. Other embodiments are also described.

A device and a method for treating a medical condition include a reversible member disposed in a patient's gastro-intestinal tract, and a dispensing member coupled to the reversible member that delivers a drug and / or a noxious when a predetermined substance is detected. In a different embodiment, the device and method of the present invention include a polymer infused with a drug and disposed into a preformed shell inside the gastric space, where it expands and hardens, releasing the drug over time. Both the casing and the polymer may be biocompatible. The present invention enables the slow-release of anti-addictive agents without patient tampering and with the appropriate dosage. Ancillary systems such as sensors, actuators, refill and recharge ports, and communication and data processing units may also be included.

A satiation device is described which includes a sheath or liner extending from the proximal or middle stomach to the distal antrum. Food ingested by the patient passes through the sheath or liner, thereby minimizing contact between the ingested food and the stomach. It is believed that over time, reduced contact between food and the stomach will result in decreased Ghrelin production by the patient and a consequent decrease in appetite. In some embodiments, the satiation device may also include a proximal pouch and / or a distal bypass tube.

Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.

The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.

The invention provides methods and pharmaceutical compositions for administering a PPARα agonist (e.g., OEA-like agonist, OEA-like compound), an OEA-like appetite reducing compound, or a FAAH inhibitor and a CB1 cannabinoid receptor antagonist to a subject in order to reduce the consumption or ingestion of food, ethanol or other appetizing substances as well as in treating appetency disorders related to the excess consumption of food, ethanol, and other appetizing substances. The combination therapy can also be useful for reducing body fat or body weight and modulating lipid metabolism.

ACE-2 modulating compounds for the treatment of body weight disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below:(R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.

The invention discloses a medicament for treating breast cancer, which comprises the following raw materials: costus root, rhizoma cyperi, radix curcumae, dried orange peel, cortex magnoliae officinalis, dangshen, fried bighead atractylodes rhizome, glossy privet fruit, angelica, milk vetch, Chinese wolfberry, radix scutellariae, coptis, tuber pinellia, morel, solanum lyratum, bupleurum, agrimony, radix rehmanniae, barbed skullcap herb, dandelion, oyster, prepared turtle shell, forsythia, euphorbia helioscopia, citron, corydalis tuber, rhizoma bolbostemmae, American ginseng, white peony root, licorice, glabrous greenbrier rhizome, chuanxiong rhizome, mint, buttercup root, tulip bulb, sarcandra glabra, prunella vulgaris, gizzard pepsin, common burreed rhizome, rhizoma zedoariae, red sage root, fried mastic and fried myrrh. The medicament disclosed by the invention has an obvious effect on treating breast cancer, can be used for treating both principal and secondary aspects of the disease, has the functions of inhibiting the growth and migration of cancer cells, improving the gastrointestinal functions of patients and improving the immunity, and does not have toxic side reactions. The effective rate reaches 92.6%, and the effect taking rate reaches 75%. The medicament disclosed by the invention has the characteristics of exact effect and low price, can be used for quickly curing the breast cancer, and can be easily accepted by patients.

The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, General Anxiety Disorder (GAD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), Social Phobia (SP), Health Anxiety (Hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar I depression disorder, bipolar II depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), Obsessive-Compulsive Disorder (OCD), Obsessive-Compulsive Personality Disorder (OCPD), Autism Spectrum Disorder (ASD), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (AMD), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, Rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, Parkinson's disease, Parkinson's disease psychosis, Huntington disease, Alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, Alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.

The invention discloses a method for breeding Bama miniature pigs. The method includes the steps that pregnant sows are fed by postconceptual age fetus growth fodder from the 92 day of pregnancy to the day of farrowing, and the postconceptual age fetus growth fodder comprises, by weight, 40-70 parts of corn, 10-30 parts of rice bran, 25-40 parts of black bean pulp, 10-20 parts of fish protein concentrate, 15-25 parts of sweet potato leaves, 30-50 parts of hair weeds, 0.5-5 parts of rhizoma atractylodis macrocephalae, 0.5-5 parts of radix scutellariae, 3-8 parts of massa medicata fermentata, 5-10 parts of radix salviae miltiorrhizae, 5-10 parts of rhamnus aurea and 0.5-2 parts of plant extract, wherein the plant extract is a water solution containing 3% of cinnamyl aldehyde, 4% of mannan oligosaccharide and 5% of carvacrol. According to the method for breeding the Bama miniature pigs, the growth activity of piglets and the reproductive performance of the sows after farrowing can be improved obviously, and the healthy growth of the Bama miniature pigs at the later period can be promoted.

Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

The invention discloses a nitrite-substituted meat processing method, and belongs to the technical field of food processing. The nitrite-substituted meat processing method comprises the following steps: selecting raw materials, carrying out pickling treatment and processing a meat product, so that the final products of the meat product are prepared; and the nitrite is substituted by a nitrite substitute during the step of carrying out pickling treatment. The nitrite substitute comprises the following components in parts by weight: 4-5 parts of monascorubin, 0.7-1.3 parts of betanin, 4-6 parts of potassium sorbate, 2-3 parts of D-sodium isoascorbate, 1.5-2.5 parts of nisin, 9-11 parts of sodium lactate, 1-2 parts of natamycin, 5-6 parts of natural vitamin E, 1-2 parts of a rosemary extract, 0.5-1.5 parts of sage essential oil, 1-2 parts of tea polyphenols, 15-16 parts of L-sodium glutamate, 0.5-1.5 parts of flavoring 5'-disodium ribonucleotide, 40-43 parts of a yeast extract, 4-5 parts of sodium tripolyphosphate and 0.5-1.5 parts of ethyl maltol. The nitrite-substituted meat processing method disclosed by the invention is simple, easy to operate and free of nitrite addition; and the prepared meat products are very good in qualities, color, luster and taste.

The invention provides a Chinese medicine pill for treating chronic dysentery. The Chinese medicine pill has the advantages of quick acting, good effect, no toxic or side effects and low cost when used for treating the chronic dysentery and comprises the following Chinese medicinal components in parts by weight: 10-15 parts of scutellaria baicalensis, 12-18 parts of atractylodes macrocephala, 15 parts of poria cocos, 5 parts of medicated leaven, 8 parts of costustoot, 10-15 parts of fructus amomi, 15-20 parts of Chinese yam, 10 parts of sophora flower, 5 parts of platycodon grandiflorum, 20 parts of cortex ailanthi, 10-15 parts of garden burnet, 20 parts of purslane and 6 parts of liquorice. The invention further provides a preparation method of the pill. The preparation method comprises the following steps of decocting, coking, stir-frying, calcining, carbonizing, grinding, sieving, mixing, airing, preparing into pills, drying and the like.

The invention discloses a composite premix for pigs and belongs to the technical field of feeds. The composite premix for pigs comprises a carrier, mineral matters, composite vitamin, amino acid, an anti-oxidant, phytase, antibacterial peptide and phytosterol. The mineral matters comprise trace element mineral matter and constant element mineral matter. The composite premix for pigs contains no antibiotic but antibacterial peptide and phytosterol. The trace elements adopted in the invention are mainly organic trace elements. Weighed according to a ratio, components of the composite premix forpigs can perform a synergistic effect, so as to avoid the antagonistic effect, raise utilization rate of additives such as trace elements for live pigs, save limited resources of inorganic mineral feeds, substantially improve the ecological environment around a pig farm, simultaneously reduce deposition of the trace elements in pigs, raise the quality of pork and guarantee the health of consumers.

Methods are described for suppressing appetite through the nasal and oral administration of a vanillylamide, thereby desensitizing gustatory or olfactory nerves and reducing the appeal of food. Long term desensitization is particularly contemplated.

A device and a method for treating a medical condition include a reversible member disposed in a patient's gastro-intestinal tract, and a dispensing member coupled to the reversible member that delivers a drug and / or a noxious when a predetermined substance is detected. In a different embodiment, the device and method of the present invention include a polymer infused with a drug and disposed into a preformed shell inside the gastric space, where it expands and hardens, releasing the drug over time. Both the casing and the polymer may be biocompatible. The present invention enables the slow-release of anti-addictive agents without patient tampering and with the appropriate dosage. Ancillary systems such as sensors, actuators, refill and recharge ports, and communication and data processing units may also be included.

The invention relates to a protein dietary fiber meal replacement powder solid beverage and applications thereof, and belongs to the field of foods. The protein dietary fiber meal replacement powder solid beverage comprises the following raw materials: 20-25 parts by weight of whey protein, 20-25 parts by weight of oat fiber, 15-25 parts by weight of soy protein isolate, 15-20 parts by weight of resistant dextrin, 10-15 parts by weight of the psyllium husks, 2-5 parts by weight of milk minerals and 2-5 parts by weight of inulin. The above-mentioned protein dietary fiber meal replacement powdersolid beverage is convenient to eat, full and rich in mouth feel and rich in nutrients, can effectively supplement proteins and minerals, and can reduce hunger, effectively reduce appetite and reduceenergy intake so as to achieve weight-losing effect. When used for people who are losing weight, the above-mentioned protein dietary fiber meal replacement powder solid beverage can effectively control the weight of the drinker by providing satiety, and can effectively avoid affecting the health of the drinker.

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

The invention relates to Bifidobacterium CECT 7765 and to the use thereof in the prevention and / or treatment of overweight, obesity and related pathologies. The invention likewise relates to the Bifidobacterium CECT7765 strain, to the cellular components, metabolites and secreted molecules thereof, to the combinations thereof with other microorganisms, and to compositions that include the preceding products, as well as to the use of one strain of the species Bifidobacterium pseudocatenulatumo and to the use of the CECT 7765 strain for preventing and / or treating obesity; excess weight; hyperglycemia; and diabetes, preferably type-2 Diabetes Mellitus; hepatic steatosis or fatty liver; dyslipidemia; metabolic syndrome; immune system dysfunction associated with obesity and excess weight; and an imbalance in the composition of the intestinal microbiota associated with obesity and excess weight.

The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below:(R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A-26-A27-A28-R1wherein the definitions of A1 to A28 and R1 to R3 are provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.

The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.

A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject.